Literature DB >> 19184977

A finite mixture survival model to characterize risk groups of neuroblastoma.

Sally Hunsberger1, Paul S Albert, Wendy B London.   

Abstract

Neuroblastoma is a childhood cancer with patients experiencing heterogeneous survival outcomes despite aggressive treatment. Disease outcomes range from early death to spontaneous regression of the tumor followed by cure. Owing to this heterogeneity, it is of interest to identify patients with similar types of neuroblastoma so that specific types of treatment can be developed. Oncologists are especially interested in identifying patients who will be cured so that the minimum amount of a potentially toxic treatment can be given to this group of patients. We analyze a large cohort of neuroblastoma patients and develop a finite mixture model that uses covariates to predict the probability of being in a cure group or other (one or more) risk groups. A prediction method is developed that uses the estimated probabilities to assign a patient to different risk groups. The robustness of the model and the prediction method is examined via simulation by looking at misclassification rates under misspecified models.

Entities:  

Mesh:

Year:  2009        PMID: 19184977      PMCID: PMC4559264          DOI: 10.1002/sim.3543

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  Estimation in a Cox proportional hazards cure model.

Authors:  J P Sy; J M Taylor
Journal:  Biometrics       Date:  2000-03       Impact factor: 2.571

2.  Cure fraction estimation from the mixture cure models for grouped survival data.

Authors:  Binbing Yu; Ram C Tiwari; Kathleen A Cronin; Eric J Feuer
Journal:  Stat Med       Date:  2004-06-15       Impact factor: 2.373

3.  Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.

Authors:  W B London; R P Castleberry; K K Matthay; A T Look; R C Seeger; H Shimada; P Thorner; G Brodeur; J M Maris; C P Reynolds; S L Cohn
Journal:  J Clin Oncol       Date:  2005-08-22       Impact factor: 44.544

4.  Applications of a mixture survival model with covariates to the analysis of a depression prevention trial.

Authors:  J B Greenhouse; N P Silliman
Journal:  Stat Med       Date:  1996-10-15       Impact factor: 2.373

5.  A note on quantifying follow-up in studies of failure time.

Authors:  M Schemper; T L Smith
Journal:  Control Clin Trials       Date:  1996-08

6.  The use of mixture models for the analysis of survival data with long-term survivors.

Authors:  V T Farewell
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

7.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

Authors:  R C Seeger; G M Brodeur; H Sather; A Dalton; S E Siegel; K Y Wong; D Hammond
Journal:  N Engl J Med       Date:  1985-10-31       Impact factor: 91.245

8.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

Review 9.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Authors:  G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

Review 10.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.